Join ARMGO at the World Orphan Drug Congress USA, Boston, USA, April 23 – 25, 2024

April 23–25, 2024

Boston, USA

Join ARMGO at the World Orphan Drug Congress USA, Boston, USA, April 23 – 25, 2024

ARMGO Pharma will be attending World Orphan Drug Congress USA 2024, one of the biggest and most influential meetings for stakeholders interested in orphan drugs and rare diseases. The event will bring together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers.

The event is a great opportunity to meet and network with professionals from all disciplines to advance orphan drug development and enable faster access to potentially life-saving therapies, like ARM210, ARMGO’s clinical-stage orphan drug candidate for catecholaminergic polymorphic ventricular tachycardia (CPVT) and Ryanodine Receptor 1 Related Myopathy (RYR1-RM).

The event will take place in Boston, USA.

Request a meeting with us via ARMGO’s website.

 

 

Attendee:

Yael Webb, PhD, JD Chief Operating Officer & General Counsel

 

 

Hermann-Josef Kaiser, PhD, Vice President Business Development

ARMGO Pharma Discusses Results of RYR1-RM Phase 1b Trial of Rycal® ARM210 in Webinar by RYR1 Foundation

In a recent webinar ARMGO Pharma discussed data from the Phase 1b trial of our Rycal® ARM210 (S48168) for the treatment of Ryanodine Receptor 1 Related Myopathies (RYR1-RM), an orphan muscle disease. The event took place on Monday, February 26, 2024 and was organized by the RYR1 Foundation and chaired by the Foundation’s President, Dr. Michael Goldberg. Our CEO and co-author of the study Dr. Gene Marcantonio, was joined by Dr. Payam Mohassel, the principal investigator and Dr. Joshua Todd, the lead associate investigator of the study.

Join ARMGO at AHA Scientific Sessions, Philadelphia, USA, November 11 – 13, 2023

November 11-13, 2023

Philadelphia, USA

 

Join ARMGO at AHA Scientific Sessions, Philadelphia, USA, November 11 – 13, 2023

ARMGO will be attending American Heart Association’s Scientific Sessions 2023, the biggest global congress for advancement in cardiovascular science and medicine. The event in Philadelphia, USA will bring together cardiologists, researchers, and experts from the pharma industry.

This meeting is a great opportunity for us to explore the latest progress in clinical practice and cardiovascular drug development and discuss ARMGO’s Rycal® therapeutics with other companies and cardiac experts.

On Saturday November 11, researchers from Amsterdam University Medical Centers (UMC) and Henry Ford Health will present a biomarker study in heart failure on poster board no. 2272. The study was led by Yigal Pinto, MD, PhD and shows new mechanistic implications for disease progression.

 

Request a meeting with us by contacting us here.

 

Attendees:

Gene Marcantonio, MD, PhD, Chief Executive Officer

 

Yigal Pinto, MD, PhD, Medical Director

ARMGO presented at 23RD ANNUAL BIOTECH IN EUROPE FORUM in Basel, Switzerland, September 20 – 21, 2023

September 20–21, 2023

Basel, Switzerland

 

ARMGO presented at 23RD ANNUAL BIOTECH IN EUROPE FORUM in Basel, Switzerland, September 20 – 21, 2023

The ANNUAL BIOTECH IN EUROPE FORUM organized by SACHS ASSOCIATES is a compact meeting of leading investment, pharma, and biotech companies discussing Europe’s Biotech industry. In its 23rd Annual Edition, this global event addressed current pharma trends and the biotech investment landscape. Many experts shared their outlook for the industry for 2024.

ARMGO’s Vice President, Business Development, Hermann-Josef Kaiser, PhD took part in a panel alongside industry experts from Forbion, EQT Life Science, Cardior Pharmaceuticals GmbH, Neurimmune AG, and Bayer AG. The session, ‘The Heart is in Again – Are We Seeing a Renaissance of Cardiovascular & Cardiometabolic Panel’ provided critical insight into the latest wave of innovations and regulatory challenges to develop new therapeutics for heart disease.

In a separate session Hermann also presented ARMGO’s novel small molecule therapeutics, Rycals, as well as an update on the phase 2 clinical trial to treat the life-threatening arrhythmia, Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

The meeting took place in-person in Basel, Switzerland.

 

Attendee:

Hermann-Josef Kaiser, PhD, Vice President Business Development

Join ARMGO at BIO International Convention, Boston, USA, June 05 – 08, 2023

June 05 – 08, 2023

Boston, USA

 

Join ARMGO at BIO International Convention, Boston, USA, June 05 – 08, 2023

ARMGO will be attending BIO International Convention 2023, the biggest global event for the biotechnology industry. The event will host biotechnology and pharma leaders for one week of networking and business development.

This conference is a great opportunity to connect with other companies working on cardiac and skeletal muscle diseases to discuss the science behind ARMGO’s Rycal® therapeutics as well as our pipeline.

The event will take place in-person in Boston, USA and ARMGO will participate in the BIO One-on-One Partnering.

Request a meeting with us via the partnering platform.

 

Attendee:

Yael Webb, PhD, JD Chief Operating Officer / General Counsel

 

Hermann-Josef Kaiser, PhD, Vice President Business Development

Join ARMGO at 19th Orphan Drugs & Rare Disease Global Congress 2023, London, UK, April 3 – 4, 2023

April 3-4, 2023

London, UK

 

Join ARMGO at 19th Orphan Drugs & Rare Disease Global Congress 2023, London, UK, April 3 – 4, 2023

The Orphan Drugs and Rare Disease Global Congress is Europe’s leading conference for orphan drug development. The event focuses on practical strategies and best practices on challenges, innovations, and concepts surrounding orphan drugs and rare diseases. It is a great opportunity to engage with stakeholders across the community committed to deliver life-changing breakthroughs for patients in need.

The event will take place in-person in London, UK.

Meet us on site by contacting us.

 

Attendee:

Rachael Russell, Vice President Clinical Operations

 

Hermann-Josef Kaiser, PhD, Vice President Business Development

Join ARMGO at Rare Disease Innovation & Partnership Summit in Philadelphia, USA, March 21 – 23, 2023

March 21–26, 2022

Philadelphia, USA

 

Join ARMGO at Rare Disease Innovation & Partnership Summit in Philadelphia, USA, March 21 – 23, 2023

The Rare Disease Innovation & Partnership Summit is one of the world’s leading conferences bringing together key stakeholders in orphan drug development. It is a great opportunity to engage with patient advocacy groups for rare diseases and companies developing and commercializing orphan drugs to deliver life-changing breakthroughs for patients in need.

The event will take place in-person in Philadelphia, USA.

Meet us on site by contacting us.

 

Attendee:

Yael Webb, PhD, JD / General Counsel

Join ARMGO at BIO-EUROPE in Leipzig, Germany, October 24 – 26, 2022

October 24–26, 2022

Leipzig, Germany / Virtual

 

Join ARMGO at BIO-EUROPE in Leipzig, Germany, October 24 – 26, 2022

BIO-EUROPE is one of the world’s leading conferences in biotech and pharma business development. Connect with thousands of potential partners to propel life-science deal making. The event will take place in-person in Leipzig, Germany, as well as virtually.

Connect with us on the partnering site to request a meeting.

 

Attendee:

Hermann J. Kaiser, Business Development Advisor